Northwest & Ethical Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Northwest & Ethical Investments’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-561	Closed	-$428K	–	567
2026 Q1	$428K	Sell	561 -154	-22%	-$118K	0.01%	412
2025 Q4	$553K	Buy	715 +255	+55%	+$173K	0.01%	389
2025 Q3	$258K	Buy	+460	New	+$260K	0.01%	457
2023 Q2	–	Sell	-1,398	Closed	-$1.15M	–	410
2023 Q1	$1.15M	Hold	1,398	–	–	0.04%	294
2022 Q4	$1.01M	Sell	1,398 -830	-37%	-$612K	0.03%	298
2022 Q3	$1.53M	Sell	2,228 -61	-3%	-$38.4K	0.06%	256
2022 Q2	$1.35M	Hold	2,289	–	–	0.05%	272
2022 Q1	$1.6M	Buy	+2,289	New	+$1.45M	0.05%	267
2020 Q2	–	Sell	-2,788	Closed	-$1.36M	–	411
2020 Q1	$1.36M	Buy	2,788 +69	+3%	+$28.5K	0.08%	259
2019 Q4	$1.02M	Sell	2,719 -986	-27%	-$332K	0.05%	320
2019 Q3	$1.03M	Buy	+3,705	New	+$1.1M	0.05%	312
2015 Q3	–	Sell	-16,000	Closed	-$8.16M	–	218
2015 Q2	$8.16M	Buy	+16,000	New	+$7.81M	0.54%	55

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northwest & Ethical Investments's REGN Position: Q2 2026 in Review

Northwest & Ethical Investments sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 561 shares — an estimated $428K sold.

Northwest & Ethical Investments first reported a position in REGN in Q2 2015 and held it in 12 quarters. The position peaked at $8.16M in Q2 2015. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Northwest & Ethical Investments reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Northwest & Ethical Investments sold 561 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $428K.
Northwest & Ethical Investments first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 12 quarters.
Northwest & Ethical Investments's Regeneron Pharmaceuticals position peaked at $8.16M in Q2 2015.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.